Outcomes of patients with esophageal and gastric cancer in Sri Lanka: A retrospective survival analysis.


Journal

Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598

Informations de publication

Date de publication:
Apr 2023
Historique:
medline: 8 5 2023
pubmed: 6 5 2023
entrez: 6 5 2023
Statut: ppublish

Résumé

Esophageal carcinoma is the fourth most common cancer among males and sixth most common cancer among females in Sri Lanka. Gastric cancer is less common, but its incidence is gradually rising. We conducted a retrospective analysis of survival of esophageal and gastric cancer patients treated at National Cancer Institute, Maharagama, Sri Lanka. Patients with esophageal and gastric cancer treated in three selected oncology units of the National Cancer Institute, Maharagama during 2015 and 2016 were included in the study. Data on clinical and pathological factors were extracted from clinical records. Overall survival (OS), defined as time to death or loss to follow-up, was the primary endpoint. Univariate and multivariate analyses of survival were performed using the log-rank test and Cox proportional-hazard model, respectively. The study population comprised 374 patients with a median age of 62 years (interquartile range 55-70). Majority (64%) were male and had squamous cell carcinoma (58%). In the sample, 20% were gastric cancers, while 71% were esophageal cancers, and 9% had gastro-esophageal junction tumors. The 2-year OS was 19% in patients treated with curative intent (95% confidence interval [CI] 14-26 months) with those receiving neoadjuvant chemotherapy, followed by radical surgery having the highest survival (P < 0.001, hazard ratio 0.25 [95% CI 0.11-0.56]). Median OS was 2 months (95% CI 1-2 months) in patients treated with palliative intent. Our results suggest that the outcome of patients with esophageal and gastric cancer is poor in Sri Lanka. Early detection and greater utilization of multimodality treatment could improve outcomes of these patients.

Identifiants

pubmed: 37148006
pii: JCanResTher_2023_19_8_294_373836
doi: 10.4103/jcrt.jcrt_817_21
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S294-S299

Auteurs

Sidath Wijesekera (S)

Department of Clinical Oncology, National Cancer Institute; Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa, Sri Lanka.

Lanka Alagiyawanna (L)

Department of Clinical Oncology, National Cancer Institute; Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa, Sri Lanka.

Vimukthini Peiris (V)

Department of Clinical Oncology, National Cancer Institute; Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa, Sri Lanka.

Damitha Chathuranga Silva (DC)

Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa, Sri Lanka.

Tiromi Rupasinghe (T)

Department of Clinical Oncology, National Cancer Institute; Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa, Sri Lanka.

Jayantha Balawardena (J)

Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa; Department of Clinical Oncology, General Sir John Kotalawela Defence University Hospital, Boralesgamuwa, Sri Lanka.

Thurairajah Skandarajah (T)

Department of Clinical Oncology, National Cancer Institute; Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa, Sri Lanka.

Nadarajah Jeyakumaran (N)

Department of Clinical Oncology, National Cancer Institute; Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa, Sri Lanka.

Dehan Gunasekera (D)

Department of Clinical Oncology, National Cancer Institute; Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa, Sri Lanka.

Minoli Bandusena (M)

Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Batticaloa; Department of Surgical Oncology, Teaching Hospital, Anuradhapura, Sri Lanka.

Nuradh Joseph (N)

Sri Lanka Cancer Research Group, Sri Lanka College of Oncologists; Department of Clinical Oncology, Teaching Hospital, Batticaloa, Sri Lanka.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH